PSAT1 overexpression is documented across multiple malignancies — including non-small cell lung cancer (NSCLC), breast cancer, gastric cancer, colon cancer, and ovarian cancer — where it drives tumorigenesis and malignant progression (62–67). Here, PSAT1 is linked to non-small cell lung carcinoma.